See more : Saga plc (SAGA.L) Income Statement Analysis – Financial Results
Complete financial analysis of Vaccinex, Inc. (VCNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaccinex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Yunnan Water Investment Co., Limited (6839.HK) Income Statement Analysis – Financial Results
- INEOS Styrolution India Limited (INEOSSTYRO.NS) Income Statement Analysis – Financial Results
- FibroGen, Inc. (0IL8.L) Income Statement Analysis – Financial Results
- 3 Sixty Risk Solutions Ltd. (SAYFF) Income Statement Analysis – Financial Results
- Toukei Computer Co., Ltd. (4746.T) Income Statement Analysis – Financial Results
Vaccinex, Inc. (VCNX)
About Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 570.00K | 100.00K | 900.00K | 50.00K | 523.00K | 724.00K | 90.00K | 316.00K |
| Cost of Revenue | 0.00 | 207.00K | 169.00K | 2.00K | 199.00K | 1.03M | 160.00K | 115.00K |
| Gross Profit | 570.00K | -107.00K | 731.00K | 48.00K | 324.00K | -309.00K | -70.00K | 201.00K |
| Gross Profit Ratio | 100.00% | -107.00% | 81.22% | 96.00% | 61.95% | -42.68% | -77.78% | 63.61% |
| Research & Development | 16.57M | 13.98M | 17.16M | 21.55M | 25.67M | 22.35M | 16.55M | 16.03M |
| General & Administrative | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Other Expenses | 0.00 | -175.00K | 43.00K | -575.00K | 152.00K | 165.00K | -40.00K | -4.00K |
| Operating Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.34M | 26.97M | 21.03M | 20.46M |
| Cost & Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.54M | 28.01M | 21.19M | 20.58M |
| Interest Income | 0.00 | 2.00K | 809.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00K | 2.00K | 809.00K | 489.00K | 0.00 | 392.00K | 1.36M | 2.99M |
| Depreciation & Amortization | 119.00K | 207.00K | 169.00K | 307.00K | 249.00K | 223.00K | 206.00K | 178.00K |
| EBITDA | -19.75M | -19.61M | -21.40M | -28.06M | -31.61M | -28.90M | -17.20M | -10.78M |
| EBITDA Ratio | -3,464.56% | -19,606.00% | -2,475.33% | -56,110.00% | -6,044.74% | -3,714.50% | -23,264.44% | -6,356.01% |
| Operating Income | -22.89M | -19.91M | -22.49M | -28.33M | -32.02M | -27.28M | -21.10M | -20.26M |
| Operating Income Ratio | -4,014.91% | -19,906.00% | -2,498.89% | -56,662.00% | -6,121.41% | -3,768.09% | -23,448.89% | -6,411.08% |
| Total Other Income/Expenses | 2.63M | 91.00K | 110.00K | -520.00K | 152.00K | -2.24M | 2.35M | 6.32M |
| Income Before Tax | -20.25M | -19.82M | -22.38M | -28.85M | -31.86M | -29.52M | -18.76M | -13.94M |
| Income Before Tax Ratio | -3,552.81% | -19,815.00% | -2,486.67% | -57,702.00% | -6,092.35% | -4,077.07% | -20,843.33% | -4,412.34% |
| Income Tax Expense | 0.00 | -93.00K | 852.00K | 458.00K | 152.00K | -1.85M | 1.28M | 2.99M |
| Net Income | -20.25M | -19.72M | -23.23M | -29.31M | -32.02M | -29.52M | -18.72M | -13.94M |
| Net Income Ratio | -3,552.81% | -19,722.00% | -2,581.33% | -58,618.00% | -6,121.41% | -4,077.07% | -20,802.22% | -4,412.34% |
| EPS | -43.68 | -97.59 | -170.04 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| EPS Diluted | -43.68 | -97.59 | -169.11 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| Weighted Avg Shares Out | 463.65K | 202.08K | 136.63K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
| Weighted Avg Shares Out (Dil) | 463.65K | 202.08K | 137.38K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
The 3 Best Biotech Stocks Under $1 to Buy for January
Vaccinex, Inc. to Present at CHDI's 17th Annual HD Therapeutics Conference Meeting
8 Penny Stocks To Buy Now According To Insiders In 2022
5 Penny Stocks To Buy Now According To Insiders In 2022
Vaccinex And 4 Other Penny Stocks Bought By Insiders
4 Hot Penny Stocks To Buy Under $5 Right Now
Vaccinex Stock (VCNX): Why The Price Surged Up Today
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021
Source: https://incomestatements.info
Category: Stock Reports